Search Orphan Drug Designations and Approvals
-
| Generic Name: | Cabiralizumab |
|---|---|
| Date Designated: | 01/11/2016 |
| Orphan Designation: | Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor |
| Orphan Designation Status: | Designated/Withdrawn |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Five Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
-
